Johnson & Johnson has released its financial results for the second quarter of 2025, revealing a 4.1% increase in sales to customers, amounting to $45.636 billion, compared to $43.830 billion in the same period of the previous year. The gross profit stood at $30.651 billion, a slight increase from $30.450 billion, representing a 0.7% rise. The cost of products sold increased by 12.0%, reaching $14.985 billion, up from $13.380 billion. Net earnings per share (diluted) remained stable at $5.53 for the six-month period. The effective tax rate decreased to 17.2% from 17.6% in the previous year. The company experienced a reduction in research and development expenses, which saw a 3.5% decline, totaling $6.741 billion compared to $6.982 billion in the prior period. Additionally, Johnson & Johnson reported a significant net other income of $7.214 billion, contrasting with an expense of $3.057 billion in the previous year. No specific outlook or guidance was provided in the released documents.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.